COVID-19: vaccine's progress

Microb Biotechnol. 2021 Jul;14(4):1246-1257. doi: 10.1111/1751-7915.13818. Epub 2021 May 7.

Abstract

Under the pressure of the COVID-19 pandemic, vaccines were developed and rolled out into mass vaccination campaigns at incredible speed. What normally takes a decade was worked out within a year. Vaccines were produced along many different platforms ranging from inactivated whole virus vaccines over adenovirus-vectored vaccines, recombinant protein vaccines and nanoparticles to mRNA vaccines. Several vaccines went through preclinical testing and completed successful phase 1 to phase 3 clinical trials. The first evaluations of national vaccination campaigns document astonishing high levels of protection against disease. The present article summarizes the published reports leading to these striking achievements with vaccines based on different concepts.

MeSH terms

  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Genetic Vectors
  • Humans
  • Pandemics
  • Vaccines, Synthetic

Substances

  • COVID-19 Vaccines
  • Vaccines, Synthetic